Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.59
+0.10001.82%
Post-market: 5.58-0.0100-0.18%19:46 EDT
Volume:3.04M
Turnover:16.95M
Market Cap:1.14B
PE:-9.67
High:5.64
Open:5.54
Low:5.50
Close:5.49
52wk High:7.01
52wk Low:2.98
Shares:204.66M
Float Shares:198.20M
Volume Ratio:1.85
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5782
EPS(LYR):-0.5344
ROE:-105.48%
ROA:-50.15%
PB:7.96
PE(LYR):-10.46

Loading ...

BRIEF-Savara Announces Chief Financial And Administrative Officer Transition

Reuters
·
Jun 09

Savara shareholders approve charter amendment doubling authorized common shares to 600 million

Reuters
·
Jun 09

Savara says CFO Dave Lowrance stepping down for health reasons

TIPRANKS
·
Jun 09

Savara COO Robert Lutz to take CFO role as Lowrance steps down for health reasons

Reuters
·
Jun 09

Savara - Robert Lutz to Assume Role of Chief Financial Officer

THOMSON REUTERS
·
Jun 09

Savara - Dave Lowrance to Step Down as Chief Financial and Administrative Officer Effective July 15, 2026

THOMSON REUTERS
·
Jun 09

Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)

TIPRANKS
·
Jun 03

Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)

TIPRANKS
·
May 29

Savara management to join Jefferies Global Healthcare Conference fireside chat, host investor meetings

Reuters
·
May 28

A Look At Savara (SVRA) Valuation After Positive Phase 3 IMPALA 2 Data And MOLBREEVI Launch Preparations

Simply Wall St.
·
May 23

Analysts Are Bullish on Top Healthcare Stocks: Savara (SVRA), Adagio Medical Holdings (ADGM)

TIPRANKS
·
May 21

Savara presents poster at ATS 2026 International Conference on IMPALA-2

TIPRANKS
·
May 20

Savara says molgramostim cuts aPAP biomarkers in IMPALA-2 Phase 3 trial poster

Reuters
·
May 20

Savara Presented New Biomarker Data From the Impala-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the American Thoracic Society (ATS) International Conference 2026

THOMSON REUTERS
·
May 20

Savara publishes corporate presentation focused on autoimmune PAP and MOLBREEVI program

Reuters
·
May 20

Savara says molgramostim lifts exercise distance in IMPALA-2 aPAP Phase 3 trial

Reuters
·
May 19

Savara Announces New Exercise Capacity Data From the Impala-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap)

THOMSON REUTERS
·
May 19

LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

TIPRANKS
·
May 16

A Look At Savara (SVRA) Valuation As MOLBREEVI Advances And Q1 2026 Results Highlight Cash And Funding Plan

Simply Wall St.
·
May 16

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Encompass Health (EHC) and SI-Bone (SIBN)

TIPRANKS
·
May 13